Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Hayes

Showing results (191-200 of 336) with videos related to

Pageof 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2017
American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology WorkforceKaren M Winkfield, Christopher R Flowers, Jyoti D Patel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 23, 2006
New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survivalChristine B Ambrosone, Timothy R Rebbeck, Gareth J Morgan, et al.
The New England Journal of Medicine|August 3, 2012
Combination anastrozole and fulvestrant in metastatic breast cancerRita S Mehta, William E Barlow, Kathy S Albain, et al.
Annals of Surgical Oncology|September 12, 2008
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrenceKandice E Kilbride, M Catherine Lee, Alexis V Nees, et al.
The Oncologist|January 24, 2012
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430Anne F Schott, William E Barlow, Kathy S Albain, et al.
Clinical Pharmacology and Therapeutics|July 4, 2006
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentSilvana Borges, Zeruesenay Desta, Lang Li, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 2022
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDaniel L Hertz, Julie A Douglas, Robert M Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral NeuropathyDaniel L Hertz, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast Cancer Research and Treatment|January 21, 2009
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry, James M Rae, Lang Li, et al.
Breast Cancer Research and Treatment|September 13, 2005
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapyAnne F Schott, Marilyn A Roubidoux, Mark A Helvie, et al.
Pageof 34

Showing results (191-200 of 336) with videos related to

Sort By:
Pageof 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2017
American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology WorkforceKaren M Winkfield, Christopher R Flowers, Jyoti D Patel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 23, 2006
New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survivalChristine B Ambrosone, Timothy R Rebbeck, Gareth J Morgan, et al.
The New England Journal of Medicine|August 3, 2012
Combination anastrozole and fulvestrant in metastatic breast cancerRita S Mehta, William E Barlow, Kathy S Albain, et al.
Annals of Surgical Oncology|September 12, 2008
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrenceKandice E Kilbride, M Catherine Lee, Alexis V Nees, et al.
The Oncologist|January 24, 2012
Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430Anne F Schott, William E Barlow, Kathy S Albain, et al.
Clinical Pharmacology and Therapeutics|July 4, 2006
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatmentSilvana Borges, Zeruesenay Desta, Lang Li, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 1, 2022
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDaniel L Hertz, Julie A Douglas, Robert M Miller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2018
Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral NeuropathyDaniel L Hertz, Kelley M Kidwell, Kiran Vangipuram, et al.
Breast Cancer Research and Treatment|January 21, 2009
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohortN Lynn Henry, James M Rae, Lang Li, et al.
Breast Cancer Research and Treatment|September 13, 2005
Clinical and radiologic assessments to predict breast cancer pathologic complete response to neoadjuvant chemotherapyAnne F Schott, Marilyn A Roubidoux, Mark A Helvie, et al.
Pageof 34